Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1996-06-04
1999-02-02
Shah, Mukund J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
5142358, 514241, 514242, 514252, 514255, 544 60, 544120, 544182, 544212, 544238, 544295, 544357, 544405, A01N 3154, A01N 4366, C07D41700, C07D40100
Patent
active
058665684
ABSTRACT:
The invention concerns pharmaceutically useful compounds of the formula I, in which A.sup.1, A.sup.2, A.sup.3, A.sup.4, B.sup.1, m, Ar, W, X, Y, Z and R.sup.1 have any of the meanings defined herein, and their pharmaceutically acceptable salts, and pharmaceutical compositions containing them. The novel compounds possess endothelin receptor antagonist activity and are useful, for example, in the treatment of diseases or medical conditions in which elevated or abnormal levels of endothelin play a significant causative role. The invention further concerns processes for the manufacture of the novel compounds and the use of the compounds in medical treatment.
REFERENCES:
patent: 5270313 (1993-12-01), Burri et al.
patent: 5292740 (1994-03-01), Burri et al.
patent: 5420129 (1995-05-01), Breu et al.
patent: 5464853 (1995-11-01), Chan et al.
patent: 5594021 (1997-01-01), Chan et al.
Clozel et al., Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist, Nature, vol. 365, pp. 759-761. Oct. 1993.
Douglas et al., Novel receptor antagonists welcome a new era in endothelin biology, Tr. Pharmacol. Sci., vol. 15, pp. 313-316. Sep. 1994.
Ferro et al., Drugs. 1996, 51(1), 12-27.
Winn et al., J. Med. Chem. 1996, 39, 1039-1048.
Whiting et al., British Journal of Pharmacology, 1995, 114, 194P.
Chan et al., Biochemical and Biophysical Research Communications, 1994, 201(1), 228-234.
Webb, D.J., Journal of Human Hypertension, 1996, 10, 383-386.
Kiowksi et al., The Lancet, 1995, 346, 732-736.
Willette et al., The Journal of Pharmacology and Experimental Therapeutics, 1997, 280, 695-701.
DiCarlo et al., American Journal of Physiology, 1995, 269, L690-L697.
Giaid et al., New England Journal of Medicine, 1993, 328, 1732-1739.
Pousset et al., European Heart Journal, 1997, 18, 254-258.
Ito et al., Circulation, 1994, 89, 2198-2203.
Sakai et al., Nature, 1996, 384, 353.
Mathew et al., Mayo Clinic Proceedings, 1996, 71, 769-777.
Kowala et al., American Journal of Pathology, 1995, 146, 819-826.
Benigni et al., Kidney International, 1993, 44, 440-444.
Deray et al., Nephrol, Dial Transplant, 1992, 7, 300-305.
Gellai et al., Journal of Pharmacologya nd Experimental Therapeutics, 1995, 275, 200-206.
Tomita et al., N. Engl. J. Med., 1989, 321(16), 1127.
Willette et al., Stroke: A Journal of Cerebral Circulation, 1994, 25, 2450-2456.
Ehrenreich et al., Res. Exp. Med., 1992, 192, 257-268.
Patel et al., Journal of Cerebral Blood Flow and Metabolism, 1996, 16(5), 950-958.
Estrada et al., American Journal of Hypertension, 1994, 7(12), 1085-1089.
Mattoli et al., Journal of Allergy and Clinical Immunology, 1991, 88, 376-384.
Springall et al., Lancet, 1991, 337, 697-701.
Itoh et al., Bulletin of Tokyo Med & Dental Univ., 1996, 43(2), 45-51.
R.D. Desai et al., "Studies in Sulphonamides: Part II. Preparation of N.sup.1 -Heterocyclic Substituted Sulphonamides from Alpha-naphthylamine and Evaluation of their Antibacterial Properties", Jour. Indian Chem. Soc., Pages 115-118, vol. 46, No. 2, 1969.
R.D. Desai et al., "Studies in Sulphonamides: Part IV. Some N.sup.6 -Heterocyclic Sulphonamides from 2-Naphthylamine as possible Antibacterial Agents", J. Indian Chem. Soc., Pages 411-414, vol. 46, No. 5, 1969.
P. Mamalis et al., "142. Some Heterocyclic N-Oxides", J. Chem. Soc., Pages 703-705, 1950.
Chemical Astracts, vol. 84, No. 15, 1976, 84:100672y.
Chemical Abstracts, vol. 100, No. 15, 1984, 100:131420t.
Chemical Abstracts, vol. 106, No. 17, 1987, 106:133792p (corresponds to JP61257960).
Himel et al., "Fluorescent Analogs of Insecticides and Synergists. Synthesis and Reactions of Active-Site Directed Fluorescent Probes", Journal Agr. Food Chem., vol. 19, No. 6, 1971, pp. 1175-1180.
Shigehara et al., "Preparation of Pyridine Derivatives and their Salts as Phospholipase A.sub.2 Inhibitors", Chemical Abstracts, vol. 122, No. 25, 1995, 122:314455g.
STN Printout identifying compounds disclosed in PCT 90-009787 and Japan 61-257960.
The Discovery of Sulfonamide Endothelin Antagonists and the Development of the Orally Active ET.sub.A Antagonist 5-(Dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesul fonamide, Journal of Medicinal Chemistry, Feb. 4, 1994, vol. 37, No. 3, pp. 329-331.
Identification of a New Class of ET.sub.A Selective Endothelin Antagonists by Pharmacophore Directed Screening, Biochemical and Biophysical Research Communications, May 30, 1994, vol. 201, No. 1, pp. 228-234.
Pharamacological Characterization of Bosentan, a New Potent Orally Active Nonpeptide Endothelin Receptor Antagonist, Journal Pharmacol. Exp. Therap., 1994, 270, 228-235.
Pages copied from a book of abstracts provided in an International Business Communications Conference entitled "Endothelin Inhibitors-Advances in Therapeutic Application and Development", Philadelphia, PA, Jun. 9-10, 1994, 33 pages.
Bradbury Robert Hugh
Butlin Roger John
James Roger
Elder Richard A.
Ngo Tamthom T.
Shah Mukund J.
Zeneca Limited
LandOfFree
Heterocyclic compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocyclic compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1117666